Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.32 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19869652 | 0.80 | BRD4 (0.42) | BRD4AURKATTKAURKBINCENP | |
| SCHEMBL23164339 | 0.78 | BRD4 (0.38) | BRD4AURKATTKAURKBINCENP | |
| SCHEMBL14472272 | 0.78 | BRD4 (0.30) | BRD4 | |
| SCHEMBL11987749 | 0.78 | BRD4 (0.38) | BRD4AURKATTKAURKBINCENP | |
| SCHEMBL13512616 | 0.78 | AURKA (0.40) | BRD4AURKATTKAURKBINCENP | |
| Bromide SCHEMBL1203957 | 0.77 | BRD4 (0.38) | BRD4AURKATTKAURKBINCENP | |
| Bromide SCHEMBL1203956 | 0.75 | BRD4 (0.37) | BRD4AURKATTKAURKBINCENP | |
| SCHEMBL29037653 | 0.75 | BRD4 (0.37) | BRD4AURKATTKAURKBINCENP | |
| SCHEMBL925383 | 0.72 | BRD4 (0.35) | BRD4ALDH1A1 | |
| SCHEMBL13523160 | 0.71 | BRD4 (0.35) | BRD4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820242-A | Preparation method of 3, 5-dibromo-1-methylpyrazine-2 (1H) -ketone | 湖北广济药业股份有限公司 | 2024-04-05 | — | — | CN | claimed |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12329821-B2 | Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| CN-120004902-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119930630-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119925375-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250136620-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025081019-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2009039397-A2 | SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER | CGI PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039397-A2 | SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER | CGI PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2008033858-A2 | KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033858-A2 | KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1863766-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2006-10-12 | — | — | US | disclosed |
| WO-2006099075-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | SLC10A1, NR3C2, CYP2C8 | BRD4 2876/4885AURKA 4337/4885TTK 4089/4885 |
| US-12329821-B2 | Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BTK, CBL, SYK | BRD4 550/4885AURKA 846/4885TTK 27/4885 |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | BTK, SYK, MYD88 | BRD4 187/4885AURKA 632/4885TTK 1887/4885 |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | BTK, CNKSR1, SYK | BRD4 648/4885AURKA 852/4885TTK 265/4885 |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | BRD4 533/4885AURKA 1162/4885TTK 918/4885 |
| US-20250136620-A1 | BTK DEGRADER | BTK, CBL, LYN | BRD4 433/4885AURKA 771/4885TTK 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.